A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...

Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

Metsera and Maze Therapeutics priced their Nasdaq IPOs, raising $275M and $140M respectively. Both companies backed by ARCH ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

By Arasu Kannagi Basil (Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to ...

Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to ...

The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. Aurion focuses on regenerative therapies, Maze advances precision medicines for ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...